Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Recombinant human CXCL8 mutant

EU orphan designation number: EU/3/13/1131   
Active ingredient: Recombinant human CXCL8 mutant
Indication: Treatment of cystic fibrosis
Sponsor: ProtAffin Biotechnologie AG
Impulszentrum Graz-West, Reininghausstrasse 13a, A-8020 Graz, Österreich

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/06/2013 Centralised Orphan - Designation EMA/OD/005/13 (2013)3675 of 07/06/2013